Kodiak ends attempt at an Eylea rival as its biologic fails two of three PhIII trials

Kodiak Sciences’ attempt at making an Eylea rival for patients with various eye conditions has come to an end.

The California biotech is scrapping its late-stage biologic after it failed two of three Phase III trials. Investors halved Kodiak’s shares Click here to view original post